Summary
Twelve male patients with chronic hepatitis B were treated by the combination of recombinant human α-interferon and cyanidanol. They received 3 million units of interferon twice a week and 2,250 mg of cyanidanol daily for 24 weeks. Four patients had sustained clinical improvement in which hepatitis B e antigen and DNA polymerase disappeared from sera and aminotransferase activities fell to normal levels. Elevated pretreatment aminotransferases were associated with the response to therapy. Also, decreased number of OKT4-positive cells prior to treatment were observed among responders. Side effects were minimal and all patients tolerated treatment on an outpatient basis.
Twice weekly administration of recombinant leukocyte interferon with cyanidanol may be effective in treating chronic hepatitis when patients are appropriately selected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lindahl P, Gresser I, Leary P, et al: Interferon treatment of mice: Enhanced expression of histocompatibility antigens on lymphoid cells. Proc Natl Acad Sci USA 1976; 73:1284–1299
Trinchieri G, Santoli D: Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells: Enhancement of natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978;147: 1314–1333
Greenberg HB, Pollard RB, Lutwing LI, et al: Effect of human leukocyte interferon and hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295:517–522
Weimar W, Heijting RA, TEN Kate FJP, et al: Double-Blind study of leukocyte interferon administration in chronic HBsAg-positive hepatitis. Lancet I 1980; 336–388
Smith Ci, Weissberg J, Bernhardt L, et al: Acute Dane particle suppression with recombinant leukocyte interferon in chronic hapatitis B virus infection. J Infec Dis 1983; 148:907–913
Omata M, Imazeki F, Yokosuka O, et al: Recombinant leukocyte α interferon treatment in patients with chronic hepatitis B virus infection. Gastroenterology 1985; 88:870–880
Scullard GH, Andres LL, Greenberg HB, et al: Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside. Hepatology 1981; 1:228–232
Smith CI, Kitchen LW, Scullard GH, et al: Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection. JAMA 1982; 247:2261–2265
Lok ASF, Novick DM, Karayiannis P, et al: A randomized study of the effects of adenine arabinoside 5′-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology 1985; 5:1132–1138
Schalm SW, Heytink RA, Vanbuuren HR, et al: Acyclovir enhances the antiviral effect of interferon in chronic hepatitis B. Lancet II 1985; 358–360
Kaplan PM, Greenman RL, Gerin JL, et al: DNA-polymerase associated with human hepatitis antigen. J Virol 1973; 112:995–1005
Dusheiko G, Dibisceglie A, Bowyer S, et al: Recombinant leukocyte interferon teratment of chronic hepatitis B. Hepatology 1985; 5:556–560
Vallotton JJ, Frei PC: Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of PPD and HBsAg. Infect Immun 1981; 32:432–437
Suzuki H, Yamamoto S, Hirayama C, et al: Cyanidanol therapy for HBe-antigen-positive chronic hepatitis: a multicenter, double blind study. Liver 1986; 6:35–44
Author information
Authors and Affiliations
Additional information
This work was supported in part by a grant for the prevention of viral hepatitis from the Ministry of Health and Welfare of Japan.
Rights and permissions
About this article
Cite this article
Kanai, K., Morioka, S., Nakajima, T. et al. Treatment of chronic hepatitis B with recombinant leukocyte interferon and cyanidanol. Gastroenterol Jpn 23, 44–48 (1988). https://doi.org/10.1007/BF02918855
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02918855